BioE3 Policy Sparks Cell & Gene Therapy Revolution in India

India's BioE3 Policy (Biotechnology for Economy, Environment, Employment) is accelerating indigenous innovation in cell and gene therapies (CGT) to treat incurable diseases with precision biotherapeutics. The policy, cleared by the Union Cabinet in August 2024, establishes biomanufacturing clusters, AI-enabled research centers, and financing mechanisms to bridge lab-to-market gaps.

 

A recent DBT-BIRAC webinar (April 19, 2025) emphasized strategic collaborations to build CGT, with affordability and clinical safety as priorities. Proposals for the policy's Precision Biotherapeutics vertical are based on scalable solutions, with grants for end-to-end research and manufacturing.

 

Key impact:

 

Economic growth: Positioning India as a global CGT leader, reducing import dependency.

 

Green manufacturing: Shifting to regenerative bioprocesses in alignment with net-zero goals.

 

Skill development: Training programs and fellowships to develop biotech talent

 

Source: PIB, DBT-BIRAC, Economic Times Government